Reuters
Eye care company Alcon Inc (ALC.N: Quote, Profile, Research) said U.S. health regulators approved its Triesence injectable triamcinolone suspension for the treatment of various ophthalmic diseases. Triesence was also approved by the U.S. Food and Drug Administration to assist retinal surgeons with visualization during vitrectomy, a type of eye surgery, the company said in a statement.